Thymulin Preclinical

What It Is

Thymulin is a small zinc-dependent nonapeptide hormone produced by thymic epithelial cells (TECs). Its full structure is the cyclic-N-terminal peptide pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn complexed with a single zinc(II) ion. Without bound zinc, the apopeptide is biologically inactive — thymulin is one of the cleanest examples in endocrinology of an obligately metallopeptide hormone, where the metal cofactor is not optional but constitutive of the active species.

The peptide was first isolated by Jean-François Bach and colleagues in Paris in 1975 from porcine and human serum, where they named it "facteur thymique sérique" (FTS — serum thymic factor). The active compound was renamed "thymulin" by Dardenne, Bach, and colleagues in 1981 once its zinc-dependence was established and the synthetic peptide could be produced and standardized. Bach's group continued thymulin research at the Hôpital Necker for the next two decades, generating most of the foundational immunology characterizing the molecule's role in T-cell maturation and immune-system regulation.

Thymulin sits at a specific point in the immune system: it is one of several thymic peptides (alongside thymosin α1, thymopoietin, thymic humoral factor, and others) that mediate the thymic contribution to T-cell development and peripheral immune balance. It is mechanistically distinct from these other thymic peptides — different sequence, different receptor footprint, different downstream effects. The clinical and research interest in thymulin is concentrated in two areas: immune restoration in immunodeficient or aged subjects (where thymic output declines), and zinc deficiency contexts (where bioactive zinc-bound thymulin is among the first measurable casualties of insufficient zinc status).

In the modern peptide community, thymulin is rare. It has not achieved the popularity of thymosin α1 or the Khavinson "Thymalin" preparation despite cleaner pharmacology, in part because no commercial pharmaceutical product has ever been brought to market and because the zinc-dependence makes consistent supply more complex than for unmodified peptides. Much current lay discussion of "thymulin" actually refers to "Thymalin" — the Khavinson polypeptide-complex extract from calf thymus that is molecularly, mechanistically, and regulatorily distinct from Bach's nonapeptide.

Mechanism of Action

Thymulin's mechanism is built around its dual immunomodulatory and zinc-dependent character. Zinc binding is not incidental — it is the structural switch that determines biological activity.

• Zinc-dependent activation — The apopeptide (zinc-free thymulin) is essentially inactive. Binding one Zn²⁺ ion induces the conformational change required to bind target cellular machinery. NMR studies (Pleau et al., 1988; PMID 3356698) confirmed 1:1 Zn²⁺-thymulin stoichiometry with apparent K_d ~5 × 10⁻⁷ M at physiological pH.
• T-cell receptor maturation signaling — Thymulin binds high-affinity sites on T-cell precursors and mature T-cells, contributing to differentiation signals that drive thymocytes toward CD3+ T-cell maturity. Acts in concert with other thymic peptides rather than as a sole driver.
• Cytokine modulation — Thymulin restores IL-2 production in T-cells from immunodeficient hosts and influences IL-6 / TNF-α balance under inflammatory stress. Modulatory rather than uniformly stimulatory.
• Regulatory rather than purely immunostimulatory — Context-dependent effects: stimulates immune function where T-cell activity is depressed (aging, malnutrition, congenital deficiency), but does not hyperstimulate immune-competent subjects with normal thymic function.
• Anti-inflammatory / CNS activity — Thymulin crosses the blood-brain barrier in modest amounts and reduces neuroinflammation markers in stress and injury models (Safieh-Garabedian, Goya group reviews).
• Zinc–thymulin axis — Zinc deficiency reduces bioactive thymulin even when total apopeptide is normal. Thymulin is therefore a sensitive functional biomarker for zinc status — and zinc repletion in deficient subjects restores bioactive thymulin without changing thymic output.
• Stress / cortisol interaction — Acute stress depresses serum thymulin via HPA-mediated effects on thymic epithelium; chronic stress correlates with persistently low bioactive thymulin.
• Pituitary / hormonal interaction — Thymulin secretion is positively modulated by GH, prolactin, and thyroid hormone, and suppressed by glucocorticoids. This embeds thymulin in the broader neuroendocrine–immune axis.
• Reciprocal pituitary feedback — Brown, Sosa, Goya 1998 — thymulin stimulates prolactin and TSH release in an age-related manner, establishing reciprocal feedback between thymic immune function and anterior pituitary.
• Pain / peripheral inflammation modulation — Safieh-Garabedian and colleagues showed zinc-related thymulin biology reduces hyperalgesia and downregulates NGF and IL-1β in peripheral inflammation models.
• Gene-therapy restoration — Reggiani, Hereñú et al. (Gene Ther 2006; PMID 16645618) demonstrated thymulin gene therapy can restore circulating thymulin in thymectomized animals, validating the peptide-as-hormone framework.
• Receptor binding site — characterization gap — Despite 50 years of research, the high-affinity binding partner on T-cell precursors has not been definitively identified as a named cell-surface receptor. Binding behavior is characterized at the functional (rosette formation, T-cell maturation) level, not at the molecular-receptor level. This is a meaningful gap in the mechanism characterization.
• Complement and acute-phase interaction — Zinc-thymulin complexes modulate complement protein expression and acute-phase response in some animal models; secondary finding not central to the primary immune-axis mechanism.
• Hypothalamic-pituitary-thymic axis — Bidirectional regulation: pituitary GH/prolactin/TSH influence thymulin secretion from thymic epithelial cells, and circulating thymulin modulates pituitary hormone release. Frames thymulin as more than a purely immune peptide.
• Zinc kinetic biology — The Zn²⁺-thymulin binding is reversible; in zinc-limited environments, thymulin gives up its zinc and returns to the inactive apopeptide form. This reversibility is why serum bioactive thymulin acts as a functional zinc-status biomarker.

What the Research Shows

Thymulin has one of the longer histories of any peptide on this site — characterized in the 1970s, with steady research output through the 1990s and a smaller but continuing literature into the 2020s. The bulk of clinical-translation work was done by the Bach/Dardenne group at Necker.

• Discovery (Bach & Dardenne, 1975–1981) — Original isolation as "FTS"; subsequent identification of zinc dependence and reclassification as "thymulin."
• Zinc binding (Gastinel et al., BBA 1984; PMID 6538097) — Established 1:1 Zn²⁺ binding and conformational basis of activity.
• NMR structure (Pleau et al., FEBS Lett 1988; PMID 3356698) — NMR of Zn(II)-nonapeptide complex confirmed structural model.
• Zinc contribution (Dardenne et al., PNAS 1982; PMID 6957870) — Contribution of zinc and other metals to biological activity of the serum thymic factor.
• Stress-induced antibody rescue (Aliev et al., 1993; PMID 8407057) — Thymulin 1 ng/kg restored thymus-dependent antibody production in restraint-stressed mice. Key demonstration that thymulin rescues impaired function rather than universally stimulating.
• Aging immune decline — Multiple rodent and human observational studies of age-related decline in serum thymulin paralleling T-cell function decline.
• Zinc deficiency — Zinc-restricted animals show low bioactive thymulin despite preserved thymic mass; zinc repletion restores bioactive thymulin and immune function.
• HIV / lymphocytopenia exploratory work — 1990s studies of thymulin in T-cell-depleted states including early HIV. Partial restoration signals; effect size insufficient versus antiretroviral therapy.
• Childhood immunodeficiency — Pilot studies in children with primary immunodeficiencies; some restoration of T-cell numbers; never advanced to Phase 3.
• Neuroendocrine-immune review framework (Reggiani et al., Curr Pharm Des 2014; PMID 24588820) — Modern review characterizing thymulin's role in the neuroendocrine-immune axis.
• Gene-therapy proof-of-principle (Reggiani et al., Gene Ther 2006; PMID 16645618) — Long-term restoration of circulating thymulin in thymectomized mice and rats.
• COVID-era interest — Small reports exploring thymulin for T-cell restoration in severe COVID in elderly patients. No Phase 2/3 data.
• Bach-group Necker corpus — Jean-François Bach, Mireille Dardenne, Jean-Marie Pleau, and colleagues produced the foundational thymulin literature over approximately 20 years at Hôpital Necker in Paris. The body of work spans isolation, zinc-dependence characterization, structure-activity relationship studies, receptor binding work on T-cell precursors, and clinical pilot administration across immunodeficiency indications. This corpus is the primary scientific record for thymulin biology.
• Safieh-Garabedian pain / inflammation axis — Extended thymulin research into peripheral inflammation and pain biology, demonstrating zinc-related thymulin effects on hyperalgesia and NGF/IL-1β in rat peripheral inflammation. One of the few avenues of thymulin research extending beyond pure immunology.
• Goya / Reggiani neuroendocrine extensions — Argentine groups developed thymulin gene-therapy models and characterized the reciprocal feedback between thymulin and the anterior pituitary (prolactin, TSH). Situates thymulin within the broader neuroendocrine-immune axis.
• Zinc-thymulin clinical biomarker use — Limited clinical research using serum bioactive thymulin as a functional zinc-status biomarker in at-risk elderly, sickle cell disease, and post-surgical nutritional support cohorts. This biomarker use is more established than any therapeutic-administration protocol.

Human Data

Human evidence for thymulin spans 50 years but is mostly observational pharmacology, exploratory clinical immunology, and small interventional studies:

• Endogenous thymulin pharmacology (1970s–80s) — Bach group characterized serum thymulin across age, immunodeficiency, zinc status, and endocrine perturbations.
• Zinc–thymulin axis in humans (Cunningham-Rundles, Prasad, Mocchegiani) — Zinc-deficient subjects (often elderly, malnourished, or with sickle cell disease) have low bioactive thymulin, with restoration on zinc supplementation.
• Pediatric immunodeficiency pilots (1980s–90s) — Small open-label studies in children with selected primary immunodeficiencies. Partial T-cell restoration reported; underpowered, not blinded.
• Aging studies — Documented decline of serum thymulin with age in healthy adults; correlated with T-cell function decline and with infection rates in elderly.
• HIV-era exploratory use — Brief 1990s interest in thymulin for HIV-associated T-cell depletion; effect size insufficient against antiretroviral therapy.
• COVID-19 small studies — Preliminary 2020–2022 reports exploring thymulin for immune modulation in older severe COVID patients; very small N.
• No registrational trial — Thymulin has never been the subject of a Phase 2 or Phase 3 randomized trial at modern regulatory standards in any country.

Dosing from the Literature

No FDA-approved dose exists. Doses below come from preclinical and exploratory clinical studies. Thymulin is research-only and not appropriate for self-administration.

Reconstitution & Storage

Research-grade thymulin is supplied as lyophilized powder, typically in 1 mg or 5 mg vials. Because biological activity depends on zinc complexation, reconstitution and storage are more demanding than for typical peptides.

• Zinc binding — Reconstituted thymulin binds free zinc spontaneously when present in the diluent. Some research protocols specify sub-stoichiometric ZnCl₂ in the buffer to ensure full activation.
• Storage — Lyophilized: 2–8°C, dark. Reconstituted: 2–8°C, use within 7–14 days (shorter than typical peptides — zinc-bound complex is less stable than apopeptide). Do not freeze reconstituted solution.
• Activity verification — In rigorous research settings, biological activity is verified by rosette-formation or T-cell maturation bioassay. Outside research labs this is not feasible.
• Inspection — Clear, colorless solution. Discard if cloudy, discolored, or precipitated.

→ Use the Kalios Peptide Calculator for research-context dosing math

Side Effects & Risks

Across available preclinical and small-scale human data, thymulin has not produced major safety signals. Practical risks relate to sourcing, formulation, and the general principle of administering an unapproved immunomodulator.

• Injection site reactions — Mild; typical for SubQ/IM peptides.
• Theoretical autoimmunity — As an immunomodulator, thymulin in subjects with established autoimmune disease has theoretical risk of disease flare. Avoid in active autoimmune conditions.
• Zinc balance — Therapeutic peptide doses deliver tiny amounts of zinc; clinically irrelevant to systemic zinc balance.
• Pregnancy / lactation — Not studied; avoid.
• Active malignancy — Immune modulation in oncologic contexts requires oncology supervision; not appropriate for self-administration.
• Drug interactions — Limited data. Theoretical interactions with immunosuppressants (cyclosporine, tacrolimus, biologics) and high-dose corticosteroids.
• Purity and zinc-binding integrity — Research-grade thymulin varies in purity and in the fraction of zinc-bound (active) versus apopeptide (inactive) form. Nominally pure peptide may not be biologically active without proper complexation.
• WADA status — Not specifically named on the WADA Prohibited List as of April 2026. As an immunomodulatory peptide hormone, athletes should consult their federation given S2 umbrella interpretations.
• Long-term safety unknown — No long-duration human safety dataset. Animal studies suggest no major toxicity at research doses; extrapolation to chronic human use is speculative.

Bloodwork & Monitoring

For research use, monitoring is more about tracking the immune-axis context than thymulin-specific labs (which are not routinely available).

• Baseline CBC with differential — Lymphocyte, T-cell, NK count baseline.
• Serum zinc / RBC zinc — Zinc status is foundational; document before considering thymulin research.
• Vitamin D (25-OH) — Standard for any immune-axis work.
• Inflammation markers (hsCRP, ESR) — Baseline.
• Comprehensive metabolic panel — Liver and kidney function baseline.
• Autoimmune screening (ANA, RF) if family history — Reasonable before any immunomodulator research.
• Bioactive thymulin assay — Specialty research assay, not commercially available. Generally not useful clinically.
• Functional T-cell assays — Available only in research / transplant-center settings.

Quick Compare — Thymulin vs Thymalin vs Thymosin α1 vs TB-500

Thymulin is often confused with other thymic-derived peptides. Clear comparison:

• Thymulin vs Thymalin — Different molecules entirely. Thymulin is Bach's zinc-bound nonapeptide; Thymalin is Khavinson's polypeptide-extract preparation. Most lay usage of "thymulin" actually refers to "Thymalin."
• Thymulin vs Thymosin α1 — Different peptides, different mechanisms, different clinical statuses. Thymosin α1 is approved in many countries for hepatitis adjunct therapy with a much larger clinical evidence base.
• Thymulin vs TB-500 — Both have thymic origin but completely different functions. TB-500 is a tissue-repair peptide via actin biology; thymulin is an immune-modulator via T-cell maturation.
• Best evidence for immune restoration — Thymosin α1 has the deepest approved-indication evidence base. Thymulin remains research-stage.

→ See Thymalin profile  •  → See Thymosin α1 profile  •  → See TB-500 profile

Supportive Nutrition & Adjuncts

Because thymulin's biological activity is inseparable from zinc status, nutritional foundations matter unusually much for any thymulin-related goal — even without administering exogenous thymulin, optimizing zinc status restores endogenous bioactive thymulin in zinc-deficient subjects.

• Zinc (15–25 mg elemental, food-form preferred) — The single most relevant adjunct to anything thymulin-related. Zinc-deficient subjects have measurably low bioactive thymulin; dietary repletion or moderate supplementation restores it. Avoid chronic >40 mg/day (copper depletion).
• Copper (1–2 mg if zinc-supplementing chronically) — Standard companion to zinc.
• Vitamin D (target 40–60 ng/mL) — Broad immune-function input.
• Protein (≥1.2 g/kg) — Adequate amino-acid substrate for immune-cell biology.
• Selenium (100–200 µg) — Thyroid (which influences thymic function) and selenoenzyme-immune redox support.
• Omega-3 (2–3 g EPA/DHA) — Inflammation balance.
• Sleep (7–9 hours) — Sleep restriction depresses thymulin and broader immune endpoints. Strongest behavioral lever.
• Stress reduction — Acute and chronic stress lowers serum thymulin via cortisol-mediated suppression of thymic epithelium.
• Things to reduce — Chronic alcohol (thymic toxicity), chronic corticosteroid use without medical necessity, severe caloric restriction.

What to Expect — Timeline

Almost no controlled human dosing data exists. This is research-framework context, not a usage guide.

• Day 1–7 — In animal models, immune-restoration effects on antibody production appear within days at very low doses. No validated human subjective effect.
• Week 2–4 — In aged-animal restoration protocols, T-cell number and function shifts become measurable.
• Month 1–3 — Sustained research-dosing shows continued immune-marker improvement. Long-term human data does not exist.
• Off-study subjective experience — Most research subjects report no acute subjective effect — thymulin acts at the cellular immune level, not at receptors that produce noticeable sensation.
• Non-responders — Likely common given zinc-dependence variability, formulation quality variability, and the host-dependence of the effect (immune-competent subjects have less to gain than immunodeficient ones).
• If you feel worse — New autoimmune-spectrum symptoms warrant cessation and evaluation.

Practical User Notes

• Don't confuse with Thymalin — Different molecules with different evidence bases. Confirm which compound your source is supplying.
• Zinc status matters more than the peptide — In zinc-deficient subjects, dietary or supplemental zinc repletion restores endogenous bioactive thymulin. This is the highest-leverage practical intervention on the thymulin axis.
• Work with a qualified researcher — Activity verification, sterile handling, and dose validation are not reasonable to attempt outside a research lab.
• Source discipline — Third-party HPLC + mass spec COAs from an independent lab. There is no way to verify the zinc-binding active fraction without a bioassay.
• Don't combine with active immunosuppressants — Theoretical antagonism with cyclosporine, tacrolimus, biologics. Not appropriate during transplant immunosuppression or active autoimmune therapy.
• Storage discipline — Refrigerated, dark, used within 1–2 weeks of reconstitution. Zinc-bound complex degrades faster than typical peptides.
• Honest expectations — Modest immune-axis modulation in the right host is the most optimistic plausible effect. Immune-system "rejuvenation" is not the claim.
• Better-evidenced alternatives — Documented immune deficiency → prescription thymosin α1 (where approved). Aging-related immune decline → sleep, exercise, nutrition, stress management produce broader systemic benefit.
• Red flags to stop — New autoimmune-spectrum symptom, fever, unexplained rash, new joint pain, GI inflammation. Cessation first, evaluation second.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Thymic and immune peptides that come up alongside Thymulin:

Next Steps

Key References

1. Bach JF, Dardenne M, Pleau JM, Bach MA. Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human. Ann N Y Acad Sci. 1975;249:186-210. PMID: 1093427.
2. Dardenne M, Pleau JM, Nabarra B, Lefrancier P, Derrien M, Choay J, Bach JF. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci USA. 1982;79(17):5370-5373. PMID: 6957870.
3. Gastinel LN, Dardenne M, Pleau JM, Bach JF. Studies on the zinc binding site to the serum thymic factor. Biochim Biophys Acta. 1984;797(2):147-155. PMID: 6538097.
4. Pleau JM, Pasdeloup N, Dardenne M, Bach JF, et al. NMR study of a lymphocyte differentiating thymic factor. An investigation of the Zn(II)-nonapeptide complexes (thymulin). FEBS Lett. 1988;229(2):425-429. PMID: 3356698.
5. Aliev M, et al. Restorative effect of short term administration of thymulin on thymus-dependent antibody production in restraint-stressed mice. Immunopharmacol Immunotoxicol. 1993;15(4):369-378. PMID: 8407057.
6. Reggiani PC, Schwerdt JI, Console GM, Roggero EA, Dardenne M, Goya RG. Physiology and therapeutic potential of the thymic peptide thymulin. Curr Pharm Des. 2014;20(29):4690-4696. PMID: 24588820.
7. Reggiani PC, Hereñú CB, Rimoldi OJ, et al. Gene therapy for long-term restoration of circulating thymulin in thymectomized mice and rats. Gene Ther. 2006;13(15):1214-1221. PMID: 16645618.
8. Goya RG, Reggiani PC, Vesenbeckh SM, et al. Thymulin gene therapy prevents the reduction in circulating gonadotropins induced by thymulin deficiency in mice. Am J Physiol Endocrinol Metab. 2007;293(1):E182-E187. PMID: 17374695.
9. Brown OA, Sosa YE, Bolognani F, Goya RG. Thymulin stimulates prolactin and thyrotropin release in an age-related manner. Mech Ageing Dev. 1998;104(3):249-262. PMID: 9818732.
10. Safieh-Garabedian B, Poole S, Allchorne A, Kanaan S, Saadé NE, Woolf CJ. Zinc reduces the hyperalgesia and upregulation of NGF and IL-1β produced by peripheral inflammation in the rat. Neuropharmacology. 1996;35(5):599-603. PMID: 8887968.
11. Cunningham-Rundles S, et al. Zinc, infection, and immunity. Ann N Y Acad Sci. 1998;842:53-60.
12. Mocchegiani E, Romeo J, Malavolta M, Costarelli L, Giacconi R, Diaz LE, Marcos A. Zinc: dietary intake and impact of supplementation on immune function in elderly. Age (Dordr). 2013;35(3):839-860. PMID: 22223033.
13. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.
14. Hadden JW, Malec PH, Coto J, Hadden EM. Thymic involution in aging. Prospects for correction. Ann N Y Acad Sci. 1992;673:231-239. PMID: 1485719.
15. Hadden JW. The treatment of zinc deficiency is an immunotherapy. Int J Immunopharmacol. 1995;17(9):697-701. PMID: 8582785.